Adma Biologics, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was ADMA Bio Manufacturing at $493.1 million, 97% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was ASCENIV at $362.5 million, 71% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
519
|
510
|
426
|
258
|
154
|
81
|
42
|
29
|
17
|
23
|
11
|
| Operating segments | |||||||||||
| ADMA Bio Manufacturing |
502
share 96.6%
|
493
+18.6%
share 96.7%
|
416
+66.5%
share 97.5%
|
250
share 96.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Plasma Collection Centers |
17
share 3.4%
|
17
+62.1%
share 3.3%
|
11
+26.0%
share 2.5%
|
8
share 3.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Sales mix | |||||||||||
| ASCENIV |
433
share 83.3%
|
363
+51.3%
share 71.1%
|
240
+158.8%
share 56.2%
|
93
share 35.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| BIVIGAM |
77
share 14.9%
|
122
-14.3%
share 23.9%
|
142
+1.5%
share 33.4%
|
140
share 54.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Plasma Collection Centers |
17
share 3.4%
|
17
+62.1%
share 3.3%
|
11
+26.0%
share 2.5%
|
8
share 3.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Intermediates And Other |
-8
share -1.6%
|
9
-74.8%
share 1.7%
|
34
+99.1%
share 8.0%
|
17
share 6.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ramsey, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1368514
- Former names
- R&R ACQUISITION VI, INC (until Feb 21, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.